Dosing frequency, expenditures similar for two anti-VEGFs for wet AMD treatment

Two intravitreal anti-VEGF agents for the first-line treatment of wet age-related macular degeneration were used in similar frequency, incurring similar health care expenditures, according to a study. The retrospective cohort study included 319 patients who received Eylea (aflibercept, Regeneron) and 1,054 patients who received Lucentis (ranibizumab, Genentech) for a 6-months analysis and 57 patients who received aflibercept and 374 patients who received ranibizumab for a 12-months analysis. At 6 months, a similar number of injections was required for aflibercept (mean: 3.8 injections) and ranibizumab (mean: 3.9 injections). Expenditures were also (Read more...)

Full Story →